Bloomberg News

Amyris Advances on Deal to Develop Microorganism for BASF (1)

April 03, 2014

Amyris Inc. (AMRS:US), the biotechnology company partially owned by Total SA (FP), rose after agreeing to develop a microorganism for BASF SE. (BAS)

Amyris gained 4 percent to $4.19 at the close in New York, the most since April 1.

The company, based in Emeryville, California, will develop a microorganism that produces a “relevant target molecule” for BASF, according to a statement today. Amyris didn’t say what the molecule will do or provide terms of the deal.

The companies expect the agreement to lead to other joint efforts. Amyris uses genetically modified microorganisms to convert plant sugars into fragrance oils and farnesene, a hydrocarbon that may be processed into fuels or specialty chemicals.

Total, France’s largest oil producer, owns about 18 percent of the company, according to data (AMRS:US) compiled by Bloomberg.

To contact the reporter on this story: Justin Doom in New York at jdoom1@bloomberg.net

To contact the editors responsible for this story: Reed Landberg at landberg@bloomberg.net Will Wade, Jasmina Kelemen


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • AMRS
    (Amyris Inc)
    • $4.41 USD
    • 0.04
    • 0.91%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus